SELLAS Life Sciences Group
Hospital/Clinic - New York, NY, US
SELLAS Life Sciences Group Employees
SELLAS Life Sciences Group Senior Management
SELLAS Life Sciences Group Details
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS' second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care.
SELLAS Life Sciences Group Technologies
Email Providers
Outlook
Web Accelerators
CloudFlare
Hosting
CloudFlare Hosting
Other
Mobile Friendly
CSS and JavaScript Libraries
Highcharts JS Library